부산대학교 도서관

INTRODUCTION Both the incidence and mortality of lung cancer have been on a steady rise over the years (Bade and Dela Cruz, 2020). Lung adenocarcinoma is a kind of NSCLC [...]
This study was designed to probe the efficacy and safety of enteral nutrition support in combination with pemetrexed and cisplatin in advanced lung adenocarcinoma. To this end, patients were divided into two groups: experimental (received cisplatin + pemetrexed chemotherapy regimen + enteral nutritional emulsion) and control (received cisplatin + pemetrexed chemotherapy regimen + routine nutritional intervention). The clinical efficacy of the experimental group was better relative to the control group (P = 0.005). After chemotherapy, the experimental group exhibited a significant reduction of tumor markers, higher hemoglobin and serum albumin levels, higher immune function, and a lower inflammatory reaction relative to the control group. Moreover, the experimental group had a high score on quality of life, a lower total occurrence rate of adverse reactions, and longer overall survival and progression-free survival time than the control group. In summary, enteral nutrition support combined with cisplatin and pemetrexed chemotherapy had a higher efficacy and safety in advanced lung adenocarcinoma therapy, which could improve the overall survival and progression-free survival time of patients and did not elevate the occurrence of adverse reactions in patients. Keywords: Cisplatin, Enteral nutrition support, Lung adenocarcinoma, Pemetrexed, Safety, Survival time